Samsung takes on clinical manufacturing of Ichnos’ mAb candidate

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Robert Daly)
(Image: Getty/Robert Daly)

Related tags: Ichnos Sciences, Samsung biologics, Monoclonal antibody, Monoclonal antibodies

Samsung continues an agreement formerly signed with Glenmark to manufacture Ichnos’ mAb treatment candidate for atopic dermatitis, as the product enters Phase III clinical trials.

Samsung Biologics announced the signing of an agreement with Ichnos to manufacture the drug substance for ISB 830, a monoclonal antibody (mAb) against receptor OX40, which is currently in development as a potential treatment for moderate-to-severe atopic dermatitis.

Additionally, the product has a mechanism of action that enables the treatment of ‘a range of autoimmune diseases’, including atopic dermatitis, the companies stated.

The agreement comes as Ichnos has completed enrollment in a Phase IIb clinical study for ISB 830, with results expected during the first half of 2020, and prepares to advance the candidate into Phase III clinical trials.

A spin-out company of Glenmark, Ichnos was launched earlier this month​ with a portfolio of five clinical stage assets across the oncology, autoimmune disease, and pain therapeutics areas. 

Samsung had signed an agreement to provide process development and manufacturing services for ISB 830 with Glenmark in 2017. 

According to the companies, the prevalence of atopic dermatitis in seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) currently exceeds 80 million patients, with the market expected to grow to $18.3bn (€16.53bn) by 2027.

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Facilities: Riverview, MI USA

Facilities: Riverview, MI USA

Piramal Pharma Solutions | 26-Jul-2021 | Insight Guide

The Piramal Pharma Solutions facility in Riverview, MI, USA can support your Drug Substance (API) needs. The site has extensive experience in safely delivering...

Facilities: Morpeth, UK

Facilities: Morpeth, UK

Piramal Pharma Solutions | 26-Jul-2021 | Insight Guide

The Piramal Pharma Solutions facility in Morpeth, UK offers Active Pharmaceutical Ingredients (APIs) and oral solid drug product development, clinical...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us

Products

View more

Webinars